A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma
Ying Mei et al. identify a four-gene tumor immune-relevant signature that predicts the overall survival of melanoma patients and their response to the CTLA4 antibody ipilimumab. This study suggests a potential utility of this four-gene signature in prognosis, risk assessment, and prediction of anti-...
Main Authors: | Ying Mei, Mei-Ju May Chen, Han Liang, Li Ma |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-03-01
|
Series: | Communications Biology |
Online Access: | https://doi.org/10.1038/s42003-021-01911-x |
Similar Items
-
Anti-CTLA-4 antibody / CTLA-4 molecule immuno-modulator mechanisms and its consequences on the reinforcement of anti-melanoma immune responses
by: Melo Félix, Joana
Published: (2016) -
Diverse mechanisms regulate the surface expression of immunotherapeutic target CTLA-4
by: Helga eSchneider, et al.
Published: (2014-12-01) -
312 Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition
by: Gary Cohen, et al.
Published: (2020-11-01) -
Immunotherapeutic approaches in the treatment of melanoma
by: Donnelly, Oliver
Published: (2012) -
Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
by: Deirdre Kelly, et al.
Published: (2021-01-01)